miltefosine has been researched along with Pythiosis in 3 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
Pythiosis: A granulomatous disease caused by the aquatic organism PYTHIUM insidiosum and occurring primarily in horses, cattle, dogs, cats, fishes, and rarely in humans. It is classified into three forms: ocular, cutaneous, and arterial.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the efficacy of azithromycin (50 mg/kg, every 12 h [q12h] orally) and miltefosine (25 mg/kg, q24h orally) treatments in an experimental model of vascular/disseminated pythiosis in immunosuppressed mice." | 7.91 | Efficacy of Azithromycin and Miltefosine in Experimental Systemic Pythiosis in Immunosuppressed Mice. ( Alves, SH; de Azevedo, MI; de Jesus, FPK; Kommers, GD; Loreto, ES; Santurio, JM; Tondolo, JSM; Verdi, CM; Weiblen, C; Zanette, RA, 2019) |
| "The treatment with miltefosine demonstrated significantly lower subcutaneous lesion areas compared to the control group but was not sufficient for the complete remission of the lesions." | 5.56 | Efficacy of miltefosine therapy against subcutaneous experimental pythiosis in rabbits. ( Alves, SH; de Andrade, CM; de Jesus, FPK; Engelmann, AM; Kommers, GD; Loreto, ES; Santurio, JM; Silva, TM; Tondolo, JSM; Zanette, RA, 2020) |
| "We evaluated the efficacy of azithromycin (50 mg/kg, every 12 h [q12h] orally) and miltefosine (25 mg/kg, q24h orally) treatments in an experimental model of vascular/disseminated pythiosis in immunosuppressed mice." | 3.91 | Efficacy of Azithromycin and Miltefosine in Experimental Systemic Pythiosis in Immunosuppressed Mice. ( Alves, SH; de Azevedo, MI; de Jesus, FPK; Kommers, GD; Loreto, ES; Santurio, JM; Tondolo, JSM; Verdi, CM; Weiblen, C; Zanette, RA, 2019) |
| "The treatment with miltefosine demonstrated significantly lower subcutaneous lesion areas compared to the control group but was not sufficient for the complete remission of the lesions." | 1.56 | Efficacy of miltefosine therapy against subcutaneous experimental pythiosis in rabbits. ( Alves, SH; de Andrade, CM; de Jesus, FPK; Engelmann, AM; Kommers, GD; Loreto, ES; Santurio, JM; Silva, TM; Tondolo, JSM; Zanette, RA, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Loreto, ES | 3 |
| Tondolo, JSM | 3 |
| de Jesus, FPK | 2 |
| Engelmann, AM | 1 |
| de Andrade, CM | 1 |
| Santurio, JM | 3 |
| Zanette, RA | 2 |
| Kommers, GD | 2 |
| Silva, TM | 1 |
| Alves, SH | 3 |
| Oliveira, DC | 1 |
| Verdi, CM | 1 |
| Weiblen, C | 1 |
| de Azevedo, MI | 1 |
3 other studies available for miltefosine and Pythiosis
| Article | Year |
|---|---|
Efficacy of miltefosine therapy against subcutaneous experimental pythiosis in rabbits.
Topics: Animals; Antifungal Agents; Dermatomycoses; Disease Models, Animal; Disease Progression; Dose-Respon | 2020 |
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Bridged Bicyclo Compounds, Heterocyclic; Clarithromyci | 2018 |
Efficacy of Azithromycin and Miltefosine in Experimental Systemic Pythiosis in Immunosuppressed Mice.
Topics: Animals; Antiprotozoal Agents; Azithromycin; Immunocompromised Host; Mice; Phosphorylcholine; Pythio | 2019 |